DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

Status unconfirmed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00024414

Run by

Theradex

Starts

2001-04-01

Last updated by the study team

2008-07-24

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Arizona Oncology Associates — Tucson, Arizona, United States
• Alta Bates Comprehensive Cancer Center — Berkeley, California, United States
• Lucille Parker Markey Cancer Center, University of Kentucky — Lexington, Kentucky, United States
• Louisiana State University Health Sciences Center - Shreveport — Shreveport, Louisiana, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Veterans Affairs Medical Center - East Orange — East Orange, New Jersey, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Kimmel Cancer Center of Thomas Jefferson University - Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.